The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Open accessAbstract
Key Points: Crbn I391V mice degrade known thalidomide derivative targets and recapitulate thalidomide-induced cytopenias and teratogenicity. Degradation of Ck1α is sufficient to explain the in vivo therapeutic window of lenalidomide in del(5q) myelodysplastic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with these findings, mice harboring a homozygous CRBN I391V knock-in allele, despite exhibiting degradation of mmIKZF1/3, mmZFP91, and mmCSNK1A1 Fink et al., 2018, show increased miscarriage upon IMiD treatment compared with control mice; however, they do not exhibit IMiD-induced embryopathies resembling the human phenotype Fink et al., 2018 .”
From Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome (2018) · cites this paper as Fink et al., 2018
Experimental — accuracy not yet measuredIn the citing paper
“Intriguingly, this site corresponds to position 391 in mouse Crbn, which features the critical isoleucine variant that is responsible for the lack of IMiD activity in mouse cells, hence masking the teratogenicity of thalidomide39.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, A., Schäfer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G., Neumann, T., & Hamon, C. (2003) · Analytical Chemistry · doi:10.1021/ac0262560 · Cited by 2,425
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Self-citationThe Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Ebert, B. L., Pretz, J. L., Bosco, J., Chang, C. Y., Tamayo, P., Galili, N., Raza, A., Root, D. E., Attar, E. C., Ellis, S. R., et al. (2008) · Nature · doi:10.1038/nature06494 · Cited by 953
Self-citationThalidomide-induced Teratogenesis: History and Mechanisms
Vargesson, N. (2015) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.21096 · Cited by 912
Efficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863
Self-citationA short history of thalidomide embryopathy
Lenz, W. (1988) · Teratology · doi:10.1002/tera.1420380303 · Cited by 786
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A. P., Hájek, R., Delforge, M., Kropff, M. H., Petrucci, M. T., Catalano, J. V., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 748
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature · doi:10.1038/nature18611 · Cited by 701
Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
Kim, J. H., & Scialli, A. R. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr088 · Cited by 667
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Wang, J., Nichogiannopoulou, A., Wu, L. J., Sun, L., Sharpe, A. H., Bigby, M. E., & Georgopoulos, K. (1996) · Immunity · doi:10.1016/s1074-7613(00)80269-1 · Cited by 614
Haslett, P. A. J., Corral, L. G., Albert, M. L., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 572
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 497
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C. J., Vivek, K., Das, B. C., & Verma, A. K. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 476
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463
Chanan-Khan, A. A., Miller, K. C., Musial, L., Lawrence, D. D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0401 · Cited by 418
Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8
Wang, G. G., Calvo, K. R., Pasillas, M. P., Sykes, D. B., Häcker, H., & Kamps, M. P. (2006) · Nature Methods · doi:10.1038/nmeth865 · Cited by 408
Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z. E., Faderl, S., Cohen, E. N., et al. (2008) · Blood · doi:10.1182/blood-2007-12-130120 · Cited by 407
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Aiolos Regulates B Cell Activation and Maturation to Effector State
Wang, J.-H., Avitahl, N., Cariappa, A., Friedrich, C., Ikeda, T., Renold, A., Andrikopoulos, K., Liang, L., Pillai, S., Morgan, B. A., et al. (1998) · Immunity · doi:10.1016/s1074-7613(00)80637-8 · Cited by 321
Recognition of thalidomide defects.
SMITHELLS, R. W., & Newman, C. G. H. (1992) · Journal of Medical Genetics · doi:10.1136/jmg.29.10.716 · Cited by 276
Narrowing and genomic annotation of the commonly deleted region of the 5q− syndrome
Boultwood, J., Fidler, C., Strickson, A., Watkins, F., Gama, S., Kearney, L., Tosi, S., Kasprzyk, A., Cheng, J., Jaju, R. J., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4638 · Cited by 264
Aiolos promotes TH17 differentiation by directly silencing Il2 expression
Quintana, F. J., Jin, H., Burns, E. J., Nadeau, M., Yeste, A., Kumar, D., Rangachari, M., Zhu, C. Y., Xiao, S., Seavitt, J., et al. (2012) · Nature Immunology · doi:10.1038/ni.2363 · Cited by 259
Habermann, T. M., Lossos, I. S., Justice, G. R., Vose, J. M., Wiernik, P. H., McBride, K., Wride, K., Ervin-Haynes, A. L., Takeshita, K., PIETRONIGRO, D. D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07626.x · Cited by 248
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Schneider, R. K., Schenone, M., Ferreira, M. S. V., Kramann, R., Joyce, C. E., Hartigan, C. R., Beier, F., Brümmendorf, T. H., Germing, U., Platzbecker, U., et al. (2016) · Nature Medicine · doi:10.1038/nm.4047 · Cited by 246
Self-citationDefects in Hemopoietic Stem Cell Activity in Ikaros Mutant Mice
Nichogiannopoulou, A., Trevisan, M., Neben, S., Friedrich, C., & Georgopoulos, K. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.9.1201 · Cited by 232
Equivalent ages in mouse and human embryos
Otis, E. M., & Brent, R. L. (1954) · The Anatomical Record · doi:10.1002/ar.1091200104 · Cited by 228
Chesi, M., Matthews, G. M., Garbitt, V. M., Palmer, S. E., Shortt, J., Lefebure, M., Stewart, A. K., Johnstone, R. W., & Bergsagel, P. L. (2012) · Blood · doi:10.1182/blood-2012-02-412783 · Cited by 215
CKIα ablation highlights a critical role for p53 in invasiveness control
Elyada, E., Pribluda, A., Goldstein, R. E., Morgenstern, Y., Brachya, G., Cojocaru, G., Snir-Alkalay, I., Burstain, I., Haffner‐Krausz, R., Jung, S., et al. (2011) · Nature · doi:10.1038/nature09673 · Cited by 202
Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Schneider, R. K., Ademà, V., Heckl, D., Järås, M., Mallo, M., Lord, A. M., Chu, L. P., McConkey, M. E., Kramann, R., Mullally, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.08.001 · Cited by 188
Self-citationpSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176
An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
Ebert, B. L., Galili, N., Tamayo, P., Bosco, J., Mak, R. H., Pretz, J. L., Tanguturi, S. K., Ladd‐Acosta, C., Stone, R. M., Golub, T. R., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050035 · Cited by 162
Self-citationGene expression profiling of CD34+ cells in patients with the 5q− syndrome
Boultwood, J., Pellagatti, A., Cattan, H., Lawrie, C. H., Giagounidis, A. A. N., Malcovati, L., Porta, M. G. D., Jädersten, M., Killick, S. B., Fidler, C., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06833.x · Cited by 155
Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice
Fratta, I., Sigg, E. B., & Maiorana, K. (1965) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(65)90095-5 · Cited by 155
Saft, L., Karimi, M., Ghaderi, M., Matolcsy, A., Mufti, G. J., Kulasekararaj, A. G., Göhring, G., Giagounidis, A. A. N., Selleslag, D., Muus, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.098103 · Cited by 139
Early human development and the chief sources of information on staged human embryos
O’Rahilly, R. (1979) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0028-2243(79)90068-6 · Cited by 138
Fehniger, T. A., Uy, G. L., Trinkaus, K., Nelson, A. D., Demland, J., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., Westervelt, P., DiPersio, J. F., et al. (2011) · Blood · doi:10.1182/blood-2010-07-297143 · Cited by 107
Sekeres, M. A., Maciejewski, J. P., Giagounidis, A. A. N., Wride, K., Knight, R., Raza, A., & List, A. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5770 · Cited by 107
Mallo, M., Rey, M. D., Ibáñez, M., Calasanz, M. J., Arenillas, L., Larráyoz, M. J., Pedro, C., Jerez, A., Maciejewski, J. P., Costa, D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12354 · Cited by 89
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis
Narla, A., Dutt, S., McAuley, J. R., Al‐Shahrour, F., Hurst, S. N., McConkey, M. E., Neuberg, D. S., & Ebert, B. L. (2011) · Blood · doi:10.1182/blood-2010-11-318543 · Cited by 87
Self-citationThalidomide Syndrome in Monkeys
Delahunt, C. S., & Lassen, L. J. (1964) · Science · doi:10.1126/science.146.3649.1300 · Cited by 79
Chung, F., Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Tingle, M. D., & Ching, L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0421 · Cited by 62
The effect of thalidomide intake during 113 human pregnancies
Kajii, T., Kida, M., & Takahashi, K. (1973) · Teratology · doi:10.1002/tera.1420080208 · Cited by 55
Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans
Lu, J., Helsby, N. A., Palmer, B. D., Tingle, M. D., Baguley, B. C., Kestell, P., & Ching, L. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067793 · Cited by 51
EFFECTS OF THALIDOMIDE ON PREGNANCY IN THE RABBIT
HAY, M. F. (1964) · Reproduction · doi:10.1530/jrf.0.0080059 · Cited by 40
‘Thalidomide’ Syndrome in Baboons
Hendrickx, A. G., Axelrod, L. R., & CLAYBORN, L. D. (1966) · Nature · doi:10.1038/210958a0 · Cited by 37
Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice
Rozewski, D. M., Herman, S. E. M., Towns, W. H., Mahoney, E., Stefanovski, M. R., Shin, J. D., Yang, X., Gao, Y., Li, X., Jarjoura, D. G., et al. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9401-2 · Cited by 35
Thalidomide: Effect upon Pregnancy in the Rhesus Monkey
Lucey, J. F., & Behrman, R. E. (1963) · Science · doi:10.1126/science.139.3561.1295 · Cited by 33
Thalidomide malformations and genetic background in the rabbit
SAWIN, P. B., Crary, D. D., Fox, R. R., & Wuest, H. M. (1965) · Cellular and Molecular Life Sciences · doi:10.1007/bf02144076 · Cited by 33
Canadian Thalidomide Experience
WEBB, J. F. (1963) · JAMA · doi:10.1001/jama.1963.03710100122084 · Cited by 23
The effect of thalidomide on a prosimian: the greater galago (Galago crassicaudatus)
Butler, H. (1977) · Journal of Medical Primatology · doi:10.1159/000459764 · Cited by 17
Cited by
Sorted by citations
Donovan, K. A., An, J., Nowak, R. P., Yuan, J. C., Fink, E. C., Berry, B. C., Ebert, B. L., & Fischer, E. S. (2018) · eLife · doi:10.7554/elife.38430 · Cited by 509
Self-citationTargeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Self-citationPROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
Qi, S., Dong, J., Xu, Z., Cheng, X., Zhang, W., & Qin, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.692574 · Cited by 306
Guo, W., Qi, X., Yu, X., Liu, Y., Chung, C.-I., Bai, F., Lin, X., Lu, D., Wang, L., Chen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17997-6 · Cited by 228
Immunotherapy of multiple myeloma
Minnie, S. A., & Hill, G. R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129205 · Cited by 222
Metadata
- Authors
- Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., Svinkina, T., Nguyen, A. T., Carr, S. A., & Ebert, B. L.
- Affiliations
- Broad Institute (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-10-04
- Volume
- 132
- Issue
- 14
- Pages
- 1535-1544
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC6172563
- OpenAlex
- W2886628870
- Cited by
- 131
- References
- 62
- Citations by year
- 2026: 19 · 2025: 22 · 2024: 20 · 2023: 13 · 2022: 14 · 2021: 16 · 2020: 16 · 2019: 7 · 2018: 3
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Edward P. Evans Foundation
- Henry and Marilyn Taub Foundation
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL082945)
- National Cancer Institute (F30CA199988, P01CA108631, P50CA206963, P01CA066996)
- National Institute of General Medical Sciences (T32GM007753)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- thalidomide, lenalidomide, thalidomide derivatives, del(5q) myelodysplastic syndrome, teratogenicity, therapeutic window, E3 ubiquitin ligase
- MeSH terms
- Lenalidomide, Animals, Antineoplastic Agents, Disease Models, Animal, Female, Hematopoiesis, Male, Mice, Inbred C57BL, Myelodysplastic Syndromes, Nerve Tissue Proteins, Thalidomide, Point Mutation, Casein Kinase I, Adaptor Proteins, Signal Transducing, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
